Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial.
Zhou T, Qin S, Xu W, Tang S, Chen G, Li S, Hou J, Gao X, Shi G, Sun Z, Jin J, Chen L, Sun W, Liu B, Wang J, Meng Q, Wang D, Hu Z, He D, Yang Y, Song X, Fu C, Wang Y, Ye D, Zhang W.
Zhou T, et al.
Int J Cancer. 2023 Aug 15;153(4):792-802. doi: 10.1002/ijc.34512. Epub 2023 Apr 10.
Int J Cancer. 2023.
PMID: 36919366
Clinical Trial.